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The aim of present study was to evaluate the nephroprotective effect of probiotic formulation LOBUN 
on Cyclosporine A (CsA) induced renal dysfunction in Wistar rats. CsA (20 mg/kg body weight s.c) was 
administered for 15 days to cause renal dysfunction in Wistar rats. The probiotic formulation LOBUN 
was administered with the dose of 500 mg/kg body weight (p.o) for twice (TGI) and thrice a day (TGII). 
The samples were analyzed for the parameters like blood urine nitrogen (BUN), serum creatinine, serum 
uric acid, total serum protein and urine proteins, urine potassium, urine sodium. The renal functional 
and histopathological studies revealed that the oral administration of probiotic formulation LOBUN has 
provided appreciable renoprotection and possibly alleviated the symptoms of Chronic Kidney Disease 
(CKD) at the dose of 500 mg/kg body weight administered thrice a day and also the results were supported 
by histopathological findings.
Uniterms: Cyclosporine-A. LOBUN/effects. LOBUN/effects/evaluation. Nephroprotective activity. 
Prebiotics. Probiotics. Chronic Kidney Disease/study.
INTRODUCTION
Chronic Kidney Disease (CKD) is a potentially 
fatal health problem with an ever-increasing incidence 
and prevalence particularly in the under developed and 
developing countries whose health infrastructure is 
unable to meet the therapeutic needs of large section of 
population who are economically deprived to afford the 
high cost of dialysis and renal transplantation. CKD in 
most cases is largely under or misdiagnosed, followed 
by under treatment leading to poor clinical outcome and 
development of irreversible cardiovascular complications 
and end stage of renal disease (Andrew, Coresh, 2012). 
Research and development of appropriate therapeutics 
based on pathophysiological cascade can be envisaged to 
retard the progression of CKD and improve the quality of 
life in patients with compromised renal function.
Cyclosporine A (CsA) is a calcineurin inhibitor 
which has remained for many years as a crucial 
immunosuppressant drug with major therapeutic role in 
early kidney transplantation in various autoimmune diseases 
(Maria, Perego, Bellia, 2013). However, these therapeutic 
benefits have been unfortunately limited by the most serious 
complications like nephrotoxicity and cardiovascular 
events. CsA nephrotoxicity is associated with imbalanced 
red-ox state and associated oxidative stress in renal tubular, 
endothelial and glomerular cells. It is accomplished by the 
development of morphological changes including vascular 
injury with ischemic damage, afferent arteriolopathy, 
intestinal fibrosis, progressive glomerular sclerosis, tubular 
and renal cell apoptosis (Subha Palaneeswar, Nagarajan, 
Manjula Devi, 2014; Jinhwa, 2010).
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Hence, in the present study, we have selected CsA 
as nephrotoxic agent to induce renal dysfunction in Wistar 
rats as this model closely mimics the renal pathological 
events of humans in various aspects. The selection of 
probiotic formulation was based on the fact that oral 
administration of beneficial microbes may metabolize 
nitrogenous wastes that generally accumulate during 
renal dysfunction leading to azotemia and may serve as 
a potential dietary supplement (Koppe, Mafra, Fouque, 
2015). We had employed a probiotic formulation LOBUN 
consisting of a mixture of specific strains of beneficial 
microorganisms viz. Streptococcus thermophilus, 
Lactobacillus acidophilus, Bifidobacterium longum, 
Lactic acid bacillus (Lactobacillus sporogenes) and a 
prebiotic compound viz. Fructooligosaccharides (FOS) 
to evaluate its renoprotective potential. 
MATERIAL AND METHODS
Experimental animals
Adult, healthy, male Wistar rats weighing between 
150-200 g, maintained under controlled conditions of 
temperature (25±2 °C) and relative humidity (50-70% 
RH) were selected for this study. The rats were allowed 
standard pelleted chow and tap water ad libitum with 12 h 
duration of light and dark cycle. They were acclimatized 
to the laboratory conditions for a week and then randomly 
divided into four experimental groups of five animals 
each (Pradeep, Narasimha, 2014). All the experimental 
procedures were carried out in accordance with the 
Committee for the Purpose of Control and Supervision 
of Experiments on Animals (CPCSEA) guidelines 
(Reg. No. 168/PO/e/13/CPCSEA), Government of India.
Composition of probiotic formulation LOBUN
Each delayed release vegetable capsule of “LOBUN” 
has contained the following probiotics in a concentration 
of not less than 15 billion CFUs taken together. The 
probiotic organisms include Streptomyces thermophilus, 
Lactobacillus acidophilus, Bifidobacterium longum, 
Lactic acid bacillus (Lactobacillus sporogenes) and a 
prebiotic compound viz. FOS (100 mg).
Drugs and chemicals
Anesthetic ether (Kabra Drugs Ltd., India), CsA 
(Apollo Pharmaceuticals, Hyderabad), Ethanol (Changshu 
Yangyum Chemicals, China), Formalin (SD-Fine Chem 
Pvt. Ltd., India) and diagnostic kits for blood urea nitrogen 
(BUN), serum creatinine, serum uric acid, serum total 
protein, urinary sodium, urinary potassium, urinary protein 
estimation were purchased from Span Diagnostics Ltd., 
India.
Acute oral toxicity study of the probiotic 
formulation LOBUN in Wistar rats
The study was performed using Wistar rats as 
per Organization for Economic Co-operation and 
Development (OECD) Guidelines No. 420 (Section 4: 
Health effects). The probiotic formulation LOBUN was 
found to be nontoxic and safe up to 5000 mg/kg body 
weight by oral route. It was found that the none of the 
doses produced any signs of toxicity and the animals 
were survived for a period of 14 days. Hence, 1/10th of the 
maximum dose i.e. 500 mg/kg body weight was selected 
as test dose for the present study. 
Experimental design
The experimental animals were randomly divided 
into 4 groups of 5 rats each and were kept on treatment 
schedule as follows.
I.  Normal group animals received the vehicle of CsA 
alone i.e. Olive oil along with regular feed and water. 
This group mainly serves to study the normal renal 
physiology and histology. 
II.  Control group animals received CsA dissolved in 
olive oil at the dose of 20 mg/kg body weight (s.c) 
once daily for 15 days to induce nephrotoxicity and 
this group serves to study the renal pathology under 
the influence of nephrotoxic drug.
III.  Therapeutic group-I (TGI) rats were treated with 
CsA (20 mg/kg body weight, s.c) for 15 days fol-
lowed by the administration of probiotic formulation 
LOBUN at the dose of 500 mg/kg body weight (p.o) 
twice a day from 15th day onwards to 28th day. 
IV.  Therapeutic group-II (TGII) rats were treated with 
CsA (20 mg/kg body weight, s.c) for 15 days fol-
lowed by the administration of probiotic formulation 
LOBUN at the dose of 500 mg/kg body weight (p.o) 
thrice a day from 15th day onwards to 28th day.
Blood sample collection and analysis
The blood samples were withdrawn periodically 
from the retro orbital venous plexus of rats under ether 
anesthesia using glass capillary tube and the collected 
blood was centrifuged (2,500 rpm for 10 min) to obtain 
clear serum sample. The serum was subjected for 
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subsequent biochemical estimations of BUN, creatinine, 
uric acid and plasma proteins (Parasuraman, Raveendran, 
Kesavan, 2010).
Urine sample collection and analysis
Urine samples were collected periodically by 
placing the animals in metabolic cages. Animals had free 
access to drinking water during this collection period (i.e. 
4 h) and samples were subjected to analysis of sodium, 
potassium, urinary protein content by using standard 
method of estimation (Patel et al.,2012).
Body weight
Body weight of experimental animals under study 
was measured periodically at 0, 14 and 28th day of study 
period and assessed to evaluate therapeutic effect of the 
probiotic formulation LOBUN on body weight of the 
rats.
Histopathological study
Animals were sacrificed and the kidneys of each 
animal were isolated. The isolated kidneys were preserved 
and fixed in 10% formalin for 2 days. Following this was 
the washing step where by the kidney pieces were washed 
in running water for about 12 h. This was followed by 
dehydration with isopropyl alcohol of increasing strength 
(70%, 80% and 90%) for 12 h each. Then the final 
dehydration was done using absolute alcohol with about 
3 changes for 12 h. The clearing was done by chloroform 
with 2 changes for 15 to 20 min each. After clearing, 
the kidney pieces were subjected to paraffin infiltration 
in automatic tissue processing unit. The kidney pieces 
were then dropped into the L-shaped blocks containing 
molten paraffin quickly and allow cooling. The blocks 
were sectioned by using microtome to get the thickness 
of sections about  5 µ. The sections were taken on a micro 
slide and covered by egg albumin (sticking substance). 
Then the sections were allowed to remain in an oven at 
60 °C for 1 h, paraffin melts and egg albumin denaturates, 
thereby fixes tissues to the slide. Sections were stained by 
using eosin (acid stain) and haematoxylin (basic stain). 
All the tissue sections were examined using microscope 
for analyzing the altered architecture of tissue under the 
different components of treatment schedule (Hodgkinson, 
1970).
Statistical analysis
All the data was expressed as mean ± SEM. 
Statistical significance between different groups was 
tested by two-way ANOVA followed by Tukey’s multiple 
comparisons test using computer based fitting program 
(GraphPad Prism Version 6.03) and statistical significance 
was set at (P<0.01).
RESULTS
After treatment with probiotic formulation LOBUN, 
blood and urine samples were analyzed for the parameters 
like BUN, creatinine, uric acid, total serum protein 
(Table I-IV) and urinary protein, potassium, sodium 
(Table V-VII) respectively. Control group animals showed 
increase in concentration of the blood parameters such 
as BUN, creatinine, uric acid and reduced in case of 
total serum proteins when compared to the normal group 
animals, which indicates that the toxicity was induced 
in control group animals. After treatment with probiotic 
formulation LOBUN at the dose of 500 mg/kg body weight 
(twice a day (b.i.d) and thrice a day (t.i.d)), the TGs were 
showed significant reduction in concentrations of the 
parameters such as serum BUN, serum creatinine, serum 
uric acid and significant increase in total serum protein 
when compared to the control group. After induction 
of nephrotoxicity, urine parameters like urine protein 
concentration was increased and potassium, sodium 
concentrations were reduced in urine sample of control 
group when compared to the normal group animals. After 
TABLE I - Effect of the probiotic formulation LOBUN on blood urea nitrogen levels in nephrotoxic Wistar rats
Group
Blood urea nitrogen (mg/dL)
0th day 7th day 14th day 28th day
Normal 9.6±0.244 9.8±0.489**** 10±0.316**** 10.20±0.374****
Control 11.6±0.509 26±1.048 34.8±1.46 41.60±1.630
TGI 10.6±0.60 25.6±1.288 34.6±1.913 14.94±1.075****
TGII 10.8±0.374 24.8±1.157 34±1.303 11.92±0.68****
Note: All the values of mean ± SEM (n=5). Significant fromcontrol ****P < 0.0001.
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TABLE II - Effect of the probiotic formulation LOBUN on serum creatinine levels in nephrotoxic Wistar rats
Group
Serum creatinine (mg/dL)
0th day 7th day 14th day 28th day
Normal 0.60±0.09ns 0.62±0.066**** 0.64±0.05**** 0.60±0.031****
Control 0.8±0.044 3.32±0.152 4.44±0.102 6.32±0.217
TGI 0.84±0.05 3.34±0.143 4.46±0.05 3.60±0.151****
TGII 0.86±0.05 3.30±0.118 4.46±0.067 1.82±0.086****
Note: All the values of mean ± SEM (n=5). Significant from control ****P < 0.0001.
TABLE III - Effect of the probiotic formulation LOBUN on serum uric acid levels in nephrotoxic Wistar rats
Group
Serum uric acid (mg/dL)
0th day 7th day 14th day 28th day
Normal 2.080±0.146 2.140±0.136**** 2.140±0.068**** 2.000±0.089****
Control 2.200±0.114 4.960±0.194 7.460±0.447 7.540±0.333
TGI 2.160±0.075 4.520±0.213 7.360±0.317 5.540±0.169****
TGII 2.140±0.178 4.340±0.163 7.600±0.270 3.160±0.194****
Note: All the values of mean ± SEM (n=5). Significant from control ****P < 0.0001.
TABLE IV - Effect of the probiotic formulation LOBUN on total serum protein levels in nephrotoxic Wistar rats
Group
Total serum protein (g/dL)
0th day 7th day 14th day 28th day
Normal 6.56±0.154 6.92±0.136**** 6.88±0.128**** 6.90±0.164****
Control 6.80±0.161 4.24±0.103 2.96±0.121 2.14±0.050
TGI 6.90±0.105 4.12±0.116 3.10±0.017 5.44±0.150****
TGII 6.74±0.181 4. 28±0.159 3.160±0.0093 6.38±0.115****
Note: All the values of mean ± SEM (n=5). Significant from control ****P < 0.0001.
TABLE V - Effect of the probiotic formulation LOBUN on urinary protein levels in nephrotoxic Wistar rats
Group
Urinary protein (g/dL)
0th day 7th day 14th day 28th day
Normal 6.12±0.128 6.2±0. 202*** 6. 28±0.177**** 6. 26±0.13****
Control 6.18±0.048 7.86±0.156 9.38±0.174 11.88±0.941
TGI 6±0.083 7.92±0.168 9.32±0. 278 7.42±0.156****
TGII 6±0.086 8.02±0.182 9.36±0.180 6.70±0.091****
Note: All the values of mean ± SEM (n=5). Significant from control ****P < 0.0001.
treatment, the TGs showed significant reduction in urine 
protein concentration and sodium, potassium levels were 
significantly increased in urine. TG animals were exhibited 
significant increase in body weight than control group 
animals (Table VIII). 
Effect of probiotic formulation LOBUN on renal 
histology in nephrotoxic Wistar rats
The kidney section of normal group animals 
showed normal renal architecture i.e. normal glomerular 
Preclinical evaluation of nephroprotective potential of a probiotic formulation LOBUN on Cyclosporine-A induced renal dysfunction in Wistar rats
Braz. J. Pharm. Sci. 2017;53(2):e16041 Page 5 / 8
and normal renal interstitium (Figure 1A). The renal 
section of control group animal has showed tubular and 
glomerular injury with dilation of Bowman’s capsule 
and infiltration of cells in the interstitium and a marked 
tubular necrosis was observed (Figure 1B). However, 
the photomicrography of TGI revealed mild necrosis 
with reduced inflammatory infiltration and vacuolization 
(Figure 1C). Further with TGII, the prominence of these 
renal damages was reduced indicates that the LOBUN at 
the dose of 500 mg/kg t.i.d. might be effective in reversing 
the tubular interstitial damage (Figure 1D). 
DISCUSSION
BUN is a sensitive but not highly specific marker 
in CKD because BUN as such relatively non toxic and 
functions more as a marker for other low molecular weight 
uremic toxins (Zeba, Pandey, 2014; Shigehiko, Bellomo, 
Goldsmith, 2012). The significantly elevated BUN levels 
in control group compared to normal group indicates gross 
reduction in the number of functioning nephrons due to 
tubular necrosis.
Uremia is the prime contributing factor for the 
progression of CKD. Uremia can be defined as the 
accumulation of numerous nitrogenous molecules 
generated by microbial protein metabolism in the 
large intestine such as p-cresol, indole, phenyl acetic 
acid, cadaverine, putrescine etc. and in the blood as 
compromised renal function is unable to excrete them. In 
CKD, it was established that increased amounts of protein 
escapes digestion and absorption in the small intestine 
leading to increased content of nitrogen in the colon. 
This increased nitrogen content aids in the development 
of proteolytic species of bacteria that predominately 
ferments the proteins and generates uremic toxins. 
Saccharolytic species are those bacteria that ferment 
carbohydrates (Flore, 2012). Presently drug therapy in 
uremia proved to be unsuccessful or to a large extent, 
has not been tested. Hence efforts to study the drug 
therapy targeted to colonic micro environment may be a 
fruitful approach. This can be achieved by modulating the 
bacterial growth in colon by increasing the concentration 
of saccharolytic and decreasing the concentration of 
proteolytic species leading to reduced generation of 
uremic toxins. In colon, the main source of energy for 
bacterial growth is carbohydrates (CHO). In excess CHO 
availability, the bacteria will utilize CHO for growth and 
replication. If the CHO is deprived, the bacteria depend 
exclusively upon the available proteins for their growth 
which leads to fermentation of proteins and generation 
of uremic toxins. Thus, modulation of ration of CHO to 
protein indirectly aids the growth of saccharolytic species 
TABLE VI - Effect of the probiotic formulation LOBUN on 
urinary potassium levels in nephrotoxic Wistar rats
Group
Urinary potassium (meq/L)
0th day 28th day
Normal 7.44±0.453 7.02±0.363***
Control 6.56±0.10 4.88±0.048
TGI 7.32±0.312 6.44±0.156**
TGII 7.18±0.31 6.62±0.04**
Note: All the values of mean ± SEM (n=5). Significant from 
control ***P < 0.001, **p < 0.01.
TABLE VII - Effect of the probiotic formulation LOBUN on 
urinary sodium levels in nephrotoxic Wistar rats
Group
Urinary sodium (meq/L)
0th day 28th day
Normal 150±5.319 151±4.571***
Control 142. 2±3.337 93.4±069
TGI 149. 2±5.388 140.4±3.075**
TGII 155. 2±4.004 146.6±2.675***
Note: All the values of mean ± SEM (n=5). Significantfromcontrol 
***P < 0.001, **p < 0.01.
TABLE VIII - Effect of the probiotic formulation LOBUN on body weight in nephrotoxic Wistar rats
Group
Body weight (g)
0th day 14th day 28th day
Normal 124.8±0.860 145.33±1.101**** 163.274±0.952****
Control 122.4±0.927 105.20±0.860 102.14±0.727
TGI 124.9±0.707 107.8±0.861 122. 21±0.688****
TGII 122.9±0.842 108. 2±0.663 121.98±0.956****
Note: All the values of mean ± SEM (n=5). Significant from control ****P < 0.0001.
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(Hill, 1995). Hence, supplementation of saccharolytic 
species in this formulation might have reduced BUN 
levels in both the TGs and contributed to improved renal 
function. Here the prebiotic, FOS, beneficially affects 
the host by structurally stimulating the growth and/or 
activity of bacteria in the colon. FOS, a fermentable 
oligosaccharide also serves as a reservoir of CHO, thus 
contributing to the reduced metabolism of proteins by 
bacteria and also generation of uremic toxins. 
Serum creatinine is the breakdown product of 
creatinine phosphate in muscle and is usually produced 
at a fairly constant rate by the body depending on the 
muscle mass and is completely filtered out of blood by 
glomerular filtration and proximal tubular secretion. This 
is very little to know tubular reabsorption of creatinine. 
Serum creatinine levels were used to calculate creatinine 
clearance which regulates GFR, the gold standard for renal 
function (Zeba, Pandey, 2014). Drastic elevation of serum 
creatinine in control group is due to the renal failure and 
reflects massive reduction in the number of nephrons along 
with compromised function in surviving ones (Ramesh, 
2014). Reduction of serum creatinine reveals good 
prognostic application of probiotic formulation LOBUN 
in both TGs.
Uric acid is formed by the breakdown of purines 
and by direct synthesis from 5-phosphoribosyl phosphate 
and glutamate. In kidneys, uric acid is filtered, reabsorbed 
and secreted (Christin et al., 2015). The elevated uric acid 
(hyperurecemia) level clearly signifies that the CsA has 
drastically reduced the renal function and these elevated 
levels of uric acid might have association with the CKD 
by several ways like a) It may exacerbate other risk factors 
for CKD like hypertension, b) Directly toxic to kidney, c) 
It might be a marker of severity for some other risk factors 
like those have association with diabetes and metabolic 
syndromes. It was observed from the animal studies that 
the mild elevation in uric acid (hyperuricemia) was toxic 
to the kidneys and also caused systemic hypertension. 
Finally, uric acid may be a marker of kidney risk factor 
than a direct contributor to the kidney injury (Ryu et al, 
2013; Daniel, 2008). However, the reduction of serum 
uric acid levels in the TGs shows that the probiotic might 
have reduced the progression of CKD. The TGII was more 
significant in reducing serum uric acid than TGI. 
FIGURE 1 - Histopathology of kidney in various treatment groups.
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The reduced serum protein concentration in control 
group with reference to normal group indicates the hepatic 
dysfunction. This is because CKD is always accompanied 
by hepatorenal syndrome and thus compromising the 
synthetic ability of liver (Klammt et al., 2011). However, 
the improvement in serum protein levels in both the TGs 
indicates retardation of CKD progression and thereby 
improving hepatic function indirectly. 
Under normal physiological conditions, very small 
amount of proteins get excreted and major component 
of this is albumin (Margaret, Gehr, 2011). Proteinuria 
of persistently elevated protein content in urine signifies 
altered permeability due to tubule interstitial disease in 
control group. Persistent proteinuria leads to decrease in 
plasma oncotic pressure and subsequent edema (Anwar et 
al., 2000). Thus, a decreased urinary protein in TGI and 
TGII indicates that the probiotic might have retarded the 
further progression of CKD. 
The depression of urinary potassium levels in 
the control group with respect to normal signifies the 
disruption of potassium secretary mechanism leading 
to its retardation in the body (Emma et al., 2012); Shah, 
Kalantar-Zadeh, Kopple, 2015). However, the slight 
elevation in urinary potassium levels in TGI and TGII 
indicates stabilization of renal secretary mechanism with 
increased frequency of administration. 
The reduction in urinary sodium excretion as evident 
in control group with respect to normal clearly indicates 
glomerulotubular damage leading to retention of excessive 
amounts of sodium. This can be related as proteinuria leads 
to decreased plasma oncotic pressure and movement of 
fluid from vasculature into interstitial spaces contributing 
to edema. Thus, the reduced plasma volume triggers an 
increase in aldosterone secretion via the rennin angiotensin 
in an effort to raise the blood pressure, sodium retention 
and related cardiovascular complication (Emma et al., 
2012; Kovesdy, 2012). Thus the increase in the urinary 
sodium levels in TGII group compared to TGI indicates 
the improved glomerulotubular function. 
The body weight in control group animals reduced 
significantly with respect to normal due to increased 
skeletal muscle breakdown and reduced lean body mass 
(Anwar et al., 2000). Further proteinuria might also 
have contributed to reduction in body weight of control 
group. However, the weight gain in TGI and TGII can 
be contributed to significant reduction of muscle protein 
breakdown and proteinuria. 
Histopathological finding revealed that CsA 
administration has damaged renal architecture with 
vacuolization and images of TGI and TGII revealed 
significant reduction of tubule interstitial damage and 
moderate regeneration of renal tissues. This preclinical 
study has revealed that the oral ingestion of probiotic 
formulation LOBUN at a dose of 500 mg/kg body weight 
(t.i.d) has significant progression importance and this 
drug appear as a promising candidate to ameliorate 
CKD progression and further investigation in this 
aspect might have fruitful results in the development of 
nephroprotective agents from beneficial microorganisms.
CONCLUSION
Uremic retention molecules were generated by gut 
microbiota largely contributes to CKD progression as 
well its morbidity and the approach to reduce uremia is 
an attractive arena of research. In this regard, the present 
preclinical study evaluated and found that the oral ingestion 
of a probiotic formulation LOBUN has significantly 
reduced the pathologic concentration of various marker 
molecules of CKD by a way of probably altering the 
composition of colon microbiota and generation of uremic 
toxins. Thus, the probiotic formulation LOBUN appears 
to be a promising candidate to serve as dietary supplement 
to maintain a natural metabolic and physiological renal 
mechanism. As the safety and efficacy of various probiotic 
organisms are substantiated by number of epidemiological 
studies and it is reasonable to conclude that this probiotic 
formulation LOBUN could be a promising drug candidate 
to be incorporated into clinical regimen in strict accordance 
with the guidelines of regulatory authorities by carrying 
out further studies. 
CONFLICT OF INTEREST
Authors declared that there is no conflict of interests. 
REFERENCES
ANDREW, S.L.; CORESH, J. Chronic kidney disease. Lancet, 
v.379, n.9811, p.165-180, 2012.
ANWAR, A.S.; NAIDU, M.U.R.; VIJAYKUMAR, K.; 
PRAYAG, A.; RATNAKAR, K.S. Effect of pentoxifilline 
on cyclosporine induced nephrotoxicity in rats. Indian. J. 
Experiment. Biol., v.38, n.4, p.347-352, 2000.
CHRISTIN, G.O.; KARASIK, K.K.; ASMAR, A. Uric acid as 
a marker of kidney disease: review of the current literature. 
Diseas. Markers, v.2015, ID382918, p.1-6, 2015.
K. Venkateswarlu, T. Heerasingh, C. N. Babu, S. Triveni, S. Manasa, T. N. B. Babu
Braz. J. Pharm. Sci. 2017;53(2):e16041Page 8 / 8
DANIEL, E.W.; TIGHIOUART, H.; ELSAYED, E.F.; 
GRIFFITH, J.L.; SALEM, D.N.; LEVEY, A.S. Uric acid 
and incident kidney disease in the community. J. Am. Soc. 
Nephrol., v.19, n.6, p.1204-1211, 2008.
EMMA, J.M.; CAMPBELL, K.L.; MUDGE, D.W.; BAUER, 
J.D. Achieving salt restriction in chronic kidney disease. Int. 
J. Nephrol., v.2012, ID720429, p.1-10, 2012.
FLORE, D.; COHEN, G.; SMET, R.D.; RODRIGUEZ, M.; 
JANKOWSKI, J.; VANHOLDER, R.; ARGILES, A. 
Normal and pathologic concentrations of uremic toxins. J. 
Am. Soc. Nephrol., v.23, n.7, p.1258-1270, 2012.
HILL, M.J. Role of gut bacteria in human toxicology and 
pharmacology. London: Taylor & Francis Publishers, 1995. 
286p.
HODGKINSON A. Determination of oxalic acid in biological 
material. Clinic. Chem., v.16, n.7, p.547-57, 1970.
JINHWA, L. Use of antioxidants to prevent Cyclosporine A 
toxicity. Toxicol. Res., v.26, n.3, p.163-170, 2010.
KLAMMT, S.; WOJAK, H.J.; MITZNER, A.; KOBALL, S.; 
RYCHLY, J.; REISINGER, E.C.; MITZNER, S. Albumin-
binding capacity (ABiC) is reduced in patients with chronic 
kidney disease along with an accumulation of protein-bound 
uraemic toxins. Nephrol. Dialys. Transplant., v.27, n.6, 
p.2377-83, 2011.
KOPPE, L.; MAFRA, D.; FOUQUE, D. Probiotics and chronic 
kidney disease. Kidney. Int., v.88, n.5, p.958-66, 2015.
KOVESDY, C.P. Significance of hypo-and hypernatremia in 
chronic kidney disease. Nephrol. Dialys. Transplant, v.27, 
n.3, p.891-898, 2012.
MARGARET, B.; GEHR, T. Chronic kidney disease: detection 
and evaluation. Am. Family Phys., v.84, n.10, p.1138-1148, 
2011.
MARIA, D.C.; PEREGO, R.; BELLIA, G. Cyclosporine-
associated nephrotoxicity. J. Nephrol., v.3, n.3, p.168-180, 
2013.
PARASURAMAN, S.; RAVEENDRAN, R.; KESAVAN, R. 
Blood sample collection in small laboratory animals. J. 
Pharmacol. Pharmacother., v.1, n.2, p.87-93, 2010.
PATEL, P.K.; PATEL,M.A.;  SARALAI, M.G.; GANDHI,T.R. 
Antiurolithiatic effects of Solanum xanthocarpum fruit 
extract on ethylene-glycol-induced nephrolithiasis in rats. 
J. Young. Pharm., v.4, n.3, p.164-170, 2012.
PRADEEP KUMAR, C.H.; NARASIMHA REDDY, Y. 
Protective effect of Canavalia gladiate (sword bean) fruit 
extracts and its flavonoidal contents, against azathioprine-
induced toxicity in hepatocytes of albino rats. Toxicol. 
Environ. Chem., v.98, n.3, p.1-8, 2014.
R A M E S H ,  V. ;  G O V I N D A R A J A N ,  V. ;  O Z A ,  N . ; 
PARAMESWARAN, S.; DHANASEKARAN, B.P.; 
PRASHAD, K.V. Salivary creatinine estimation as an 
alternative to serumcreatinine in chronic kidney disease 
patients. Int. J. Nephrol., v.2014, ID742724, p.1-6, 2014.
RYU, E.S.; KIM, M.J.; SHIN, H.S.; JANG, Y.H.; CHOI, H.S.; 
JO, I.; JOHNSON, R.J.; KANG, D.H. Uric acid-induced 
phenotypic transition of renal tubular cells as a novel 
mechanism of chronic kidney disease. Am. J. Physiol. 
Renal. Physiol., v.304, n.5, p.F471-F480, 2013.
SHAH, A.P.; KALANTAR-ZADEH, K.; KOPPLE, J.D. Is there 
a role for ketoacid supplements in the management of CKD? 
Am. J. Kidney Diseas., v.65, n.5, p.659-673, 2015.
SHIGEHIKO, U.; BELLOMO, R.; GOLDSMITH, D. The 
meaning of the blood urea nitrogen/creatinine ratio in acute 
kidney injury. Clinic. Kidney J., v.5, p.187-191, 2012.
SUBHA PALANEESWARI, M.S.; NAGARAJAN, S.; 
MANJULA DEVI, A.J. Chronic kidney disease-effect of 
oxidative stress. Chinese. J. Biol., v.2014, n.216210, p.1-6, 
2014.
ZEBA, K.; PANDEY, M. Role of kidney biomarkers of chronic 
kidney disease: an update. Saudi. J. Biol. Sci., v.21, n.4, 
p.294-299, 2014.
Received for publication on 13rd March 2016
Accepted for publication on 24th January 2017
